TITLE

Clinical Trial Design and Consequences for Drug Development for Community-Acquired Pneumonia: An Industry Perspective

AUTHOR(S)
Tillotson, Glenn S.; Echols, Roger M.
PUB. DATE
December 2008
SOURCE
Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS237
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antibiotic development has decreased significantly, in part because of recent changes in regulatory requirements in the United States. These changes both decrease the probability of technical and regulatory success for a new antibiotic for which marketing approval is sought and motivate the pharmaceutical industry to focus its research efforts on other therapeutic areas. There is a growing, unmet clinical need for new antibiotics, because of bacterial resistance to approved drugs; however, there are few candidates in development, especially new oral agents for treatment of community-acquired respiratory infections. The answers to important questions about the benefit of antibacterial treatment for community-acquired pneumonia and the publication of clear guidance for future clinical studies will support future investments. We discuss the underlying issues and offer some alternative strategies to enable improvements in clinical trial design for community-acquired pneumonia.
ACCESSION #
35966291

 

Related Articles

  • A Randomized Trial of Antibiotic Streamlining in Community-Acquired Pneumonia (CAP).  // Clinical Infectious Diseases;4/1/2007, Vol. 44 Issue 7, pv 

    The article presents information on a randomized clinical trial of antibiotic streamlining in which adults with severe Community-Acquired Pneumonia (CAP) were randomized to receive standard therapy with intravenously administered antibiotics for at least 7 days. More than 80% of patients who...

  • Scenario 1: A Patient with Mild Community- Acquired Pneumonia—Introduction to Clinical Trial Design Issues. Gilbert, David N. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS121 

    A prototypical patient is presented to introduce important design issues for clinical trials of antibacterials in the treatment of community-acquired pneumonia.

  • Novexel Reports Positive Data for NXL103 in Pneumonia.  // BioWorld International;10/29/2008, Vol. 13 Issue 44, p2 

    The article reports that Novexel SA announced positive results from a Phase II trial of NXL103 in the treatment of community-acquired pneumonia (CAP). The drug is an oral streptogramin antibiotic that has potent in vitro activity against certain gram-positive bacteria such as penicillin,...

  • Molecular Diagnostics for Detection of Bacterial and Viral Pathogens in Community-Acquired Pneumonia. Nolte, Frederick S. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS123 

    Traditional microbiological methods for detection of respiratory tract pathogens can be slow, are often not sensitive, may not distinguish infection from colonization, and are influenced by previous antibiotic therapy. Molecular diagnostic tests for common and atypical causative pathogens of...

  • Macrolide regimens for CAP may not offer survival benefit.  // Infectious Disease News;Sep2012, Vol. 25 Issue 9, p25 

    The article provides information on a systematic review and meta-analysis which addressed the association between macrolide-based regimens for hospitalized patients with community-acquired pneumonia and a significant reduction in mortality compared with nonmacrolide regimens.

  • Is It Possible to Blind a Trial for Community- Acquired Pneumonia? Boucher, Helen W. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS210 

    Blinding a randomized, controlled clinical trial provides benefits on several levels but often is not perfectly executed or well described. Most recent registration trials of therapy for community-acquired pneumonia were designed and conducted as blinded trials, although the descriptions of...

  • Historical and Regulatory Perspectives on the Treatment Effect of Antibacterial Drugs for Community-Acquired Pneumonia. Singer, M.; Nambiar, S.; Valappil, T.; Higgins, K.; Gitterman, S. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS216 

    A noninferiority margin based on the treatment effect of antibacterial drugs is required for noninferiority studies of community-acquired pneumonia. A quantitative estimate of treatment effect is generally determined from placebo-controlled trials, but, since the mid-to-late 1930s, no studies...

  • Comment from Sarah Sleet - Chief Executive - Coeliac UK.  // Foods Matter (USA);Nov2008, p5 

    The author comments on the results of the clinical trials for the treatment of coeliac disease. She states that she is interested in the fact that there is a potential in the results of the trials, however, it is important to stress that there is still no pill and that a vaccine in not yet...

  • TeGenero fiasco prompts regulatory rethink. Sheridan, Cormac // Nature Biotechnology;May2006, Vol. 24 Issue 5, p475 

    The article reports on issues related to the results of phase 1 clinical trial of German biotech TeGenero AG’s monoclonal antibody designed to activate the immune system’s T cells at a clinical trials unit based at Northwick Park Hospital in Harrow, London, England. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics